Introduction

Breast cancer is the most common cancer in woman. Conventional and targeted therapies are implicated to improve survival rates; however treatment resistance, recurrence of disease and metastasis are still major challenges in breast cancer treatment. Particular subpopulations of tumor cells are recently identified to provide resistance toward cancer therapy, namely tumor initiating cells (TICs) or cancer stem cells (CSCs). CSCs have been identified in many malignancies and are hypothesized to form clonogenic core of tumor tissues. These cells could potentially originate from a more differentiated cancer cell that acquires self renewal properties, perhaps as a result of epithelial to mesenchymal transition (EMT). During tumor progression, cancer cells undergo EMT to acquire stem cell properties like invasiveness, dissemination and chemoresistance. Thus, an in situ carcinoma progresses to an invasive carcinoma and cells disseminate throughout the entire body via blood and lymphatic vessels. After dissemination, cells must undergo a mesenchymal to epithelial transition (MET) to colonize in distant organs. EMT signaling is involved in development and maintenance of BCSCs (breast cancer stem cells). Therefore for targeted therapeutic achievement of BCSCs, it is needed to have better understanding of EMT signaling and also to identify targets of the pathways.

BCSCs constitute a minority of tumor cells and characterized by expression of specific cell surface markers including EpCAM, CD24 and CD44, however other markers like
ABCG2 (ATP-binding cassette G2), CD10, CD29, CD49f, CD133 and CXCR4 (chemokine receptor type 4) have also been used to identify BCSCs[15]. BCSCs could be enriched in populations that underwent EMT due to high expression of transcription factors like Snail1, Twist1, Slug, Zebl, Zeb2, fork head box proteins FOXC1 and FOXC2[6-9]. It has been shown that both normal and malignant mammary stem/progenitor cells express high level of enzyme aldehyde dehydrogenase (ALDH) [10]. Breast cancer displays frequent intra- and inter-tumor heterogeneity as the result of genetic and epigenetic alterations that often enhance the vigour of cancer cells[11]. Therefore, characterization and understanding of origin of this phenotypic and molecular diversity is paramount to improving diagnosis, prognostic and predictive biomarkers and ultimately design of therapeutic strategies.

Molecular subtypes of breast cancer have been recognized through gene expression pattern. Both ER and PR receptors were expressed in Luminal A and B subtypes; however they differ in proliferation kinetics. Basal like subtypes are frequently triple negative (ER/PR/HER2-) and p53 mutant and are aggressive due to poor prognosis. Another subtype i.e. claudin low breast cancer is recognized by lack of claudin and cytokeratin and remains too elusive. Fragmentary reports are available to relate different subtype of breast cancer with specific markers of BCSCs. CD44+/CD24- phenotype is associated with basal and luminal subtype B breast cancer[13,14]. ALDH1+ phenotype is correlated with basal and HER2+ breast cancer[15]. Rare basal-like ER/PR-/K18/K5+ cells expressing CD44 have been identified in the luminal type A breast cancer[16]. Quiescent DNA repair capabilities and over expression of drug efflux pumps make BCSCs resistant for conventional cancer therapy[17].

Plethora of signaling pathways is involved in induction of EMT, BCSCs generation/maintenance and therapy resistance. Here is a brief review of the mechanism of EMT mediated Wnt, Notch, hedgehog, TGF-β, NF-κB and RTK signaling pathways as well as therapeutic resistance in breast cancer therapy.

**BCSCs mediated epithelial-mesenchymal transition in breast cancer metastasis**

In course of normal development, cells synchronize the process of differentiation as well as migratory pattern to gain complexity and specialization of particular cell types. Deregression in these coordination leads to cancer. EMT plays an important and intrinsic part of normal development during organogenesis and is also recognized as a key event for metastasis[18-20]. EMT is involved in process of development like formation of primitive streak, the neural crest delamination, heart valve differentiation and lung organogenesis[20].

Epithelial cells enhance their migratory capacity by acquiring mesenchymal state through a variety of changes like alteration of apico basal polarity, remodelling of intermediate filaments, microfilaments and intercellular adhesions by secretion of new matrix proteins and glycosaminoglycans. EMT reprograms the epithelial cells to promote tumor cell metastasis. EMT de-differentiates the tumor cells and acquires motility and invasiveness to spread into distant organs and further MET reboots an epithelial program for establishment of new tumor at the sites of spreading[21]. EMT further generates CSCs exhibiting resistance to therapy. EMT plays an important role during embryogenesis and healing phenomenon in healthy cells. Loss of E-cadherin (protein necessary for cell adhesion) and increase in N-cadherin are known to be classic marker for EMT and alteration in these marker are used to study and characterized EMT in vitro[22,23].

Mesenchymal phenotype required for tumor metastasis, is promoted by EMT signaling molecules produced in tumor microenvironment[24-25]. TGF-β secreted in inflamed microenvironment represses E-cadherin via stimulating the transcription factors Snail and Slug. Further, EMT activating protein Twist is activated by HIF-1, secreted in response to hypoxia. Tumorigenicity of cancer is enhanced by reduced E-cadherin, which is correlated with increased cancer grade. Protein expression in BCSCs is similar to EMT leading to decrease in E-cadherin and increase in N-cadherin as well as increase in Slug expression[6,26]. Additionally, immortalized non tumorigenic human mammary cells undergoing EMT are enriched in CSCs markers such as CD44+/CD24- and signaling proteins SOX2, OCT4[6-27]. The population of BCSCs is significantly increased when mammary epithelial cells transformed through HER2 overexpression undergo EMT in vitro.

BCSCs transit reversibly in two distinct development states EMT and MET due to cell plasticity[28-30]. The EMt cells are mainly quiescent and are localized at tumor invasive edge adjacent to tumor stroma. These cells express cell surface marker profile CD24+ and CD44+[29]. The second state is the MET in which cells express de-toxifying enzyme ALDH. BCSCs possessing both CSC markers CD24+, CD44+ and ALDH+ show the greatest tumor initiating capacity[29]. EMT and MET are interconnected in a time dependent and tissue context dependent manner. Recently, a direct link between EMT process and gain of stem cell competence is demonstrated in cultured breast cells. In particular, it was shown that the induction of EMT program not only allows cancer cells to disseminate from the primary tumor, but also promotes their self-renewal capability[31]. Furthermore, stemness and EMT markers in circulating tumor cells (CTCs) were associated with resistance to conventional anti-cancer therapies and treatment failure. EMT cells eventually enter into the next steps of tumor metastasis cascade, including intravasation, extravasation and formation of microscopic and macroscopic metastases in distant organs[9,12,33]. The roles of EMT to promote tumor cell dissemination are well supported by recent studies on CTCs and disseminated bone marrow tumor cells, both of which exhibited EMT and stemness characteristics[34,35]. Clinically, detection of five or more CTCs in 7.5 ml of peripheral blood serves as an indicator of breast cancer progression and the number of CTCs in patients with metastatic breast cancer tends to be a better indicator of tumor prognosis compared to other diagnostic means[36-39].

**Breast cancer stem cells mediated Signaling pathways**

Maintenance and production of BCSCs are dependent on the microenvironment often called stem cell niche. The microenvironment involved in BCSCs consist various factors including cytokines, nutrients, pH, oxygen pressure, extracellular matrix and immune cells[20,39]. Growth factors promote endothelial cell survival and increase the generation of invasive
BCSCs[40]. Hypoxia affects multiple molecular pathways that causes EMT and promotes BCSCs growth leading to enhance chemo/radio-resistance[41,42]. The hypoxia inducible protein carbonic anhydrase IX (CAIX) contributes to changes in local pH in response to hypoxia. CAIX can promote BCSCs proliferation via activation of mTORC1 signaling[39]. Increased activity of IL-6 and STAT3/NF-κB expression is associated with an increased number of HER2+ BCSCs[39].

Various signaling pathways having fundamental roles in regulation of self-renewal and differentiation of adult and embryonic stem cells have been linked to BCSCs[43]. Wnt, Notch and Hedgehog pathways have been implicated in resistance to therapy and an increased number of BCSCs during/after treatment. These pathways play key roles during embryonic development and homeostasis; and deregulations involved in normal breast stem cells self-renewal and differentiation result in a BCSCs phenotype. In addition, deregulation in signals associated with cell proliferation, survival and apoptosis contributes to breast cancer.

Aberrant activation of developmental signaling pathways

1. Wnt signalling: Wnt signaling pathway is crucial for embryonic development and is involved in cell fate determination, proliferation and cell migration[44]. Aberrant Wnt signaling leads to various pathological processes including cancer and neurodegenerative diseases. Wnt signaling induces and stabilizes the accumulation and translocation of β-catenin into nucleus which regulates transcription of Wnt target genes leading to build up of Snail and down-regulation of E-cadherin which ultimately induces EMT[45,46]. Canonical Wnt signaling induces the expression of Axin2 and stabilizes Snail which promotes EMT in breast cancer[47,48]. In the non-canonical, Wnt signaling activates the ERK1/2 pathway which activates β-catenin via RTK-PI3K-AKT pathway[27]. Wnt pathway target genes such as LEF1 and AXIN2 are upregulated in breast cancer[49]. Wnt signaling is important for BCSCs self-renewal[49]. Wnt1 was originally identified as a proto-oncogene because it was retrieved from an oncogenic integration site of MMTV (mouse mammary tumor virus). Secretion of Wnt ligand from cells in the microenvironment has paracrine effect on the invasive edge of tumor, increasing their secretion of Wnt ligand from cells in the microenvironment has been linked to BCSCs[43].

2. Notch signalling: Notch receptor has an important role in self renewal and cell fate decisions in mammmary gland development[52-54]. Notch pathway is crucial in determination of cell fate and progenitor cell population as it maintains a balance between cell proliferation, differentiation and apoptosis. Early breast cancer stage frequently activates Notch signaling pathway which is correlated with poor prognosis of breast cancer[52,53]. On activation, Notch receptor is cleaved by γ-secretase, releasing the intracellular subunit NICD (Notch intracellular domain), which then translocates to nucleus, interacts with other co-factors and regulates downstream targets transcriptionally. Inhibition of Notch signaling is sufficient to reduce mammosphere formation in vitro[55]. Notch signaling requires coordination with other signals like Notch to promote EMT. TGF-β increases Notch activity through Snail3, subsequently promoting Slug expression which suppresses E-cadherin[56]. Cross-talk of Wnt and Notch pathway is needed for tumorigenic phenotype[57]. Transcriptional factors like Sox2, Oct4 and Nanog act as master regulators of pluripotency. Sox4 induces changes in EMT process, accompanied by an enhanced number of cells with a CD44+/CD24- phenotype and higher invasion and mobility of cancer cells in vivo and in vitro.

3. Hedgehog signalling: Hedgehog signaling functions in multiple tissue/cell types in developing embryo to direct organogenesis, including the ventral-dorsal pattern formation in the neural tube and anterior-posterior pattern formation in the limb. Hedgehog was first identified in a genetic screen for genes required for Drosophila’s embryonic patterning. Hedgehog is an embryonic development organizer pathway that activates Gli1 and Pch1 positive modulators of hedgehog pathway, leading to BCSCs maintenance[53]. GLI1 is a downstream mediator of Hedgehog signaling which is required for BCSCs self-renewal and tumor initiation.

TNF-α/NF-κB signaling

TNF-α is a pro-inflammatory cytokine involved in inflammation, immunity, cellular homeostasis and tumor progression[58,59]. It activates NF-κB which induces transcription factors associated with EMT, such as Snail, Slug, Twist, ZEB1 and ZEB2[60,61]. NF-κB controls the expression of a variety of cytokines particularly IL-6 and IL-8, which are closely associated with CSC function. NF-κB activation is essential for BCSCs and inhibition of NF-κB activation exerts profound effects on normal breast development[62].

Transforming growth factor-β (TGF-β) signaling

TGF-β is a potent mediator of growth inhibition in a variety of cell types via inhibition of c-Myc expression and plays a crucial role in tissue regeneration, cell differentiation, embryonic development and regulation of immune system[63]. TGF-β suppresses tumor growth during early stage of tumor progression. EMT response declined the growth inhibitory response of TGF-β[29]. TGF-β and its receptors regulate transcription of various EMt regulators including Snail, Slug and Twist[29]. Crosstalk of TGF-β with other signaling pathways like Notch, Wnt, NF-κB and RTK is involved in the induction of EMT[64,65].

Receptor Tyrosine kinase (RTK) signaling

RTK has revealed the diversity in mechanisms of their activation by growth factor ligand binding to activation of intracellular tyrosine kinase domains. Mutations in RTKs and aberrant activation of their intracellular signaling pathways have been linked to cancer[66-72]. RTKs also have been involved in EMT process and tumor cell invasion. Activation of RTKs and their trafficking proteins PI3K, MAPK etc along with TGF-β are sufficient to regulate the EMT[29]. Crosstalk of RTK with Wnt and EGFR pathways has been reported in activation of EMT[29].

Over expression of various signaling mediators like TGF-β, TNF-α, Wnt, Notch and Hedgehog are established to be
activators of EMT; and induction of EMT causes stemness leading to formation and maintenance of BCSCs[73]. Suppression of the hyper activated signaling reduces tumor violence as well as EMT process[74,75]. However, neoplastic transformation of normal stem cells is known to produce BCSCs[76]. Therefore, the process of BCSC formation and EMT is not sequential. Both processes are activated with similar abnormal signaling, and promote each other. Crosstalk between various signaling pathways exerts synergistic effects in the regulation of BCSCs. Therefore, inhibition of the crosstalk between embryonic and other signaling pathways is crucial for breast cancer therapy.

Breast cancer stem cells and therapy resistance

Breast cancer starts as a local disease, but it can metastasize to the lymph nodes and distant organs. Nowadays more than 80% of patients under treatments receive adjuvant chemotherapy, although approximately 40% of patients relapse and ultimately die of metastatic breast cancer. Tumor regrowth following chemotherapy/radiotherapy can be arrested if the repopulating cells are destroyed with a selective BCSCs targeting agent[77].

BCSCs possess an invasive gene signature which correlates with increased metastasis and poor survival[30,79]. In mouse xenograft model of human triple negative breast cancer, the metastatic cancer cells in lungs express BCSCs marker CD44 and are able to regenerate tumor following transplantation in immune-suppressed mice[79]. High metastatic and invasive capability of BCSCs was also found in circulation of breast cancer patients who were undergoing or had completed treatment[80]. Various studies indicated that BCSCs are relatively resistant to traditional cancer therapies including chemotherapy and ionizing radiation in breast cancer cell line, primary mammary tumor cells and patient derived tumor xenografts[81-91]. Chemotherapy treatment enriches the cells that express markers of BCSCs. Increased ATP binding cassette (ABC) transporters and slow cycling nature of BCSCs serves as a potential mechanism for chemoresistance. Breast cancer resistance protein (BCRP) and Pgp were identified in MCF7 which is involved in MDR. HER2 and EGFR inhibitor Lapatinib, decreased the population of BCSCs, as HER2 overexpression has been shown to drive BCSCs activity[82,92].

Further, the presence of residual ALDH + cells following new adjuvant chemotherapy was found to associate with a high recurrence rate[93]. Both ALDH + and EpCAM + CD24 + CD44 + are able to enhance migration/invasion capacity, intrinsic detoxifying ability, efflux activities, DNA damage response and antioxidant defence[94-101]. Current treatment strategies and compounds targeting EMT are mainly aimed at various EMT inducing signals[102-107]. EMT also results in the resistance of the MCF7 cell line to tamoxifen.

Micro RNAs (miRNAs) are associated with normal biological processes including stem cell maintenance, differentiation and development. However, deregulation is reported in various human diseases including cancer as miRNAs act as either oncogenes or tumor suppressor genes[108-110]. The miRNAs regulate EMT via various classes such as miR-183 cluster, miR-200 clusters, miR-142, miR-221-222, miR-214 cluster and let-7. The miRNAs have a vital role in breast cancer stemness, metastasis and progression[77,111]. Targeting key EMT regulators such as ZEB1, SIP1 and SIRT1 by miR-200 family inhibits EMT progression[112,113]. Further, suppression of miR-200c expression by IL-6 has been reported in EMT progression[114].

Micro RNAs (miRNAs) are associated with normal biological processes including stem cell maintenance, differentiation and development. However, deregulation is reported in various human diseases including cancer as miRNAs act as either oncogenes or tumor suppressor genes[108-110]. The miRNAs regulate EMT via various classes such as miR-183 cluster, miR-200 clusters, miR-142, miR-221-222, miR-214 cluster and let-7. The miRNAs have a vital role in breast cancer stemness, metastasis and progression[77,111]. Targeting key EMT regulators such as ZEB1, SIP1 and SIRT1 by miR-200 family inhibits EMT progression[112,113]. Further, suppression of miR-200c expression by IL-6 has been reported in EMT progression[114].

Aberrant activation of Wnt, RTK, TGF-β, Notch and Hedgehog signalling leads to EMT converting epithelial cells to mesenchymal cell phenotype. Transcription factors such as Snail1/2, ZEB1/2, Slug, Smad, NF-κB, GLI as well as signalling protein PI3K and AKT, promote EMT via suppression of E-cadherin and induction of Vimentin. EMT is crucial for invasion, intravasation, circulation and extravasation; and ultimately leads to colonization of metastatic cells by mesenchymal to epithelial transition (MET). The EMT cells are characterized as relatively quiescent, E cadherin negative, Vimentin positive and upregulated p53 and p21; however MET cell are proliferative, E cadherin positive, Vimentin negative having downregulated p53 and p21.

Figure 1: Molecular signaling involved in induction of EMT and regulating BCSCs in breast cancer metastasis
Conclusions

The critical roles of BCSCs in breast cancer carcinogenesis highlight the demands for developing novel therapeutic strategies to eradicate this disease. Plasticity of BCSCs to alternation between EMT and MET state allows for invasion, dissemination and metastatic growth at distal organs resulting in therapeutic resistance. The plasticity could be readily identified by expression of distinct cellular markers. Targeting BCSCs mediated EMT via modulation of Wnt, Hedgehog, Notch, TNF-α/ NF-κB, TGF-β and RTK signaling pathways promises prevention of therapy resistance and disease recurrences. Various signaling pathways involved in breast cancer metastasis do not operate in isolation, but coordinated network is associated with phenotype of BCSCs. Modulation of Wnt, Hedgehog, Notch, TNF-α/NF-κB, TGF-β and RTK signaling pathways might trigger surprising compensatory pathways that could neutralize the treatment effects. Therefore, in-depth understanding of the coordinated signaling network is needed to target BCSCs with specific inhibitors in combination.

Conflicts of Interest: Authors have no conflict of interest.

Acknowledgements: Research was supported by University Grants Commission (UGC), India. AKM thanks CSIR, India, for JRF & SRF.

References

36. Pantel, K., Alix-Panabieres, C., Riethdorf, S. Cancer micrometas-
    population of blood circulating tumor cells from breast cancer patients
40. Kuonen, F., Secondini, C., Rüegg, C. Molecular pathways: emerg-
    ing junctions mediating growth, invasion, and metastasis of tumors
41. Batchelor, T.T., Gerstner, E.R., Emblem, K.E., et al. Improved tu-
    mor oxygenation and survival in glioblastoma patients who show in-
    creased blood perfusion after cediranib and chemoradiation. (2013)
42. Pece, S., Tosoni, D., Confalonieri, S., et al. Biological and molecular
    heterogeneity of breast cancers correlates with their cancer stem cell
43. Fazlilati, H., Gardaneh, M., Bahrami, T., et al. Crosstalk between
    breast cancer stem cells and metastatic niche: emerging molecular me-
44. Chakrabarti, R., Wei, Y., Hwang, J., et al. βN+63 promotes stem cell
    activity in mammary gland development and basal-like breast cancer by
45. Wang, Y., Zhou, B.P. Epithelial–mesenchymal transition in breast cancer
    progression and metastasis. (2011) Chin J Cancer 30(9): 603–
    611.
46. Reya, T., Clevers, H. Wnt signalling in stem cells and cancer. (2005)
47. Kotiyal, S, Bhattacharya S. Breast cancer stem cells and cancer-
    genic signaling crosstalk in breast cancer. (2011) Biochim Biophys
48. Dong, G., Jackson, K.W., McNicholas, E., et al. Role of Notch sig-
    naling in cell-fate determination of human mammary stem/progenitor
49. Xiao, D., Mo, Y., Li, M.T., et al. NOTCH-induced aldehyde dehy-
    drogenase 1A1 desacetylation promotes breast cancer stem cells. (2014)
    activation induces epithelial-to-mesenchymal transition through
    2935–2948.
51. Collu, G.M., Brennan, K. Cooperation between Wnt and Notch
52. Mishra, S., Vinayak, M. Ellagic acid checks lymphoma promo-
53. Das, L., Vinayak, M. Anti-carcinogenic action of curcumin by acti-
    vation of antioxidant defence system and inhibition of NF-kappaB sig-
54. Min, C., Eddy, S.F., Sherr, D.H., et al. NF-kappaB and epithelial to
    733–744.
    is required for inflammation-induced cell migration and invasion. (2009)
56. Kiyono, T., Taguchi, T., Ito-Kureha, T., et al. NF-kB non-cell-auton-
    nomously regulates cancer stem cell populations in the basal-like breast
57. Mishra, S., Vinayak, M. Anti-carcinogenic action of ellagic acid mediat-
    ed via modulation of oxidative stress regulated genes in Dalton
    suppresses Smad and non-Smad signalling in mammary epithelial cells,
    leading to EMT and inhibition of growth arrest and apoptosis. (2008)
    Oncogene 27(9): 1218-1230.
59. Janda, E., Lehmann, K., Kilišić, I., et al. Ras and TGFβ cooperativa-
    tively regulate epithelial cell plasticity and metastasis: dissection of Ras
60. Lemmon, M.A., Schlessinger, J. Cell Signaling by Receptor Tyro-
61. Maurya, A.K., Vinayak, M. Modulation of PKC signaling and in-
    duction of apoptosis through suppression of reactive oxygen species
    and tumor necrosis factor receptor 1 (TNFR1): key role of quercetin in
62. Maurya, A.K., Vinayak, M. Anticarcinogenic action of quercetin by
    downregulation of phosphatidylinositol 3-kinase (PI3K) and pro-
    tein kinase C (PKC) via induction of p53 in hepatocellular carcinoma
63. Maurya, A.K., Vinayak, M. Abstract A07: Decline in the growth of
    murine T-cell lymphoma via modulation of PI3K signaling pathway:
64. Maurya, A.K., Vinayak, M. Quercetin regresses Dalton’s lymphoma
    from human T-cell lymphoma via modulation of oxidative stress regu-
65. Lamb, R., Abl, M.P., Spence, K., et al. Wnt pathway activity in
    e67811.
BCSC Mediated Epithelial-Mesenchymal Transition Targets


